Krajina: Malta
Jazyk: angličtina
Zdroj: Medicines Authority
CLINDAMYCIN
Pfizer Hellas S.A. 243 Messoghion Ave., Neo Psychiko 15451, Athens, Greece
J01FF01
CLINDAMYCIN 150 mg/ml
CONCENTRATE FOR SOLUTION FOR INFUSION OR INJECTION
CLINDAMYCIN 150 mg/ml
POM
ANTIBACTERIALS FOR SYSTEMIC USE
Authorised
2005-10-31
Page 1 of 8 2023-0085903 PACKAGE LEAFLET: INFORMATION FOR THE USER DALACIN ® C PHOSPHATE 150 MG/ML CONCENTRATE FOR SOLUTION FOR INJECTION/INFUSION clindamycin (as clindamycin phosphate) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or your pharmacist. - If you get any of the side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET: 1. What Dalacin C Solution is and what it is used for 2. What you need to know before you are use Dalacin C Solution 3. How to use Dalacin C Solution 4. Possible side effects 5. How to store Dalacin C Solution 6. Contents of the pack and other information 1. WHAT DALACIN C SOLUTION IS AND WHAT IT IS USED FOR Dalacin C Solution is a sterile solution for injection into a vein (intravenously) or into a muscle (intramuscularly). The solution contains clindamycin phosphate which is an antibiotic used in the treatment of serious bacterial infections. 2. WHAT YOU NEED TO KNOW BEFORE YOU USE DALACIN C SOLUTION DO NOT USE DALACIN C SOLUTION: If you are allergic to clindamycin, another antibiotic called lincomycin or to any of the other ingredients of this medicine (listed in section 6). If you are experiencing diarrhoea or suffer from intestinal inflammatory disease. WARNINGS AND PRECAUTIONS Talk to your doctor or pharmacist before using Dalacin C Solution if you have any of the following conditions: have diarrhoea or usually get diarrhoea when you take antibiotics or have ever suffered from problems with your stomach or intestines (bowel disease). If you develop diarrhoea during or after using Dalacin C Solution TELL YOUR DOCTOR IMMEDIATELY since it will be necessary to stop treatment. This may be a sign of bowel inflammation (_pseudomembranous colitis_) which can occur following treatment with antibiotic Prečítajte si celý dokument
Page 1 of 13 2019- 0057284 SUMMARY OF PRODUCT CHARACTERISTICS 1. NAME OF THE MEDICINAL PRODUCT Dalacin C Phosphate 150 mg/ml Concentrate for solution for injection/infusion, 2 ml 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml of solution contains clindamycin phosphate equivalent to 150 mg clindamycin, giving 300 mg clindamycin per ampoule. Excipients with known effect Each ml of solution contains 9 mg of benzyl alcohol. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Concentrate for solution for injection/infusion. Clear colourless sterile solution with a pH of 5.5-7.0 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS For the management of serious infections due to organisms susceptible to this anti-infective. Clindamycin does not penetrate the blood/brain barrier in therapeutically effective quantities. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology Parenteral (IM or IV administration). Dalacin C Phosphate MUST be diluted prior to IV administration and should be infused slowly and should be infused over at least 10-60 minutes (see ‘ DILUTION FOR IV USE AND IV INFUSION RATES ’ at the end of the section). Dalacin C Phosphate IM administration should be used undiluted. _Adult: _ The usual daily adult dosage of Dalacin C Phosphate for infections of the intra-abdominal area, female pelvis, and other complicated or serious infections is 1800-2700 mg given in 2, 3, or 4 equal doses. Less complicated infections due to more susceptible microorganisms may respond to lower doses such as 1200-1800 mg/day administered in 3 or 4 equal doses. Doses of up to 4800 mg daily have been used successfully. Page 2 of 13 2019-0057284 Single IM injections of greater than 600 mg are not recommended nor is administration of more than 1.2 g in a single one-hour infusion. Alternatively, the drug may be administered in the form of a single rapid infusion of the first dose followed by continuous IV infusion. _ _ _Paediatric population _ Clindamycin should be dosed based on total body weight regardless o Prečítajte si celý dokument